Thursday, September 7, 2017 - 09:15

Notification of full year results date

Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the global pharmaceutical and services company, will announce its full year results for the year ended 30 June 2017 on Thursday, 28 September 2017.

A group analyst briefing will be held at 9:30am on Thursday, 28 September 2017 at Instinctif Partners’ offices at 65 Gresham Street, London EC2V 7NQ.

Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email clinigen@instinctif.com to register.

 

Contact Details

Clinigen Group plc
Shaun Chilton, Group Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
Tel: +44 (0) 1283 495 010

Numis Securities Limited
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
Tel: +44 (0) 20 7260 1000

RBC Capital Markets - Joint Broker
Marcus Jackson / Elliot Thomas / Jack Wood
Tel: +44 (0) 20 7653 4000

Instinctif Partners (media relations)
Melanie Toyne-Sewell / Alex Shaw
Email: clinigen@instinctif.com
Tel: +44 (0) 20 7457 202

 

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com

Back to News